In a world awash with information, Evaluate is here to provide clarity with best-in-class data and expert insight. 

As we come to the end of a very rocky first half of 2022, where to from here? We share a snapshot  of the pharma, biotech and medtech markets to bring you up to speed and help guide you forward. 



Is the famine over for M&A?
Was this the worst quarter for IPOs?
How have private groups fared?
Share price performance: who’s up and who’s down?